We are pulmonary hypertension (PH) professionals united in our vision for a world without pulmonary vascular disease (PVD). We believe we can achieve this together, and we won’t stop until we do.
PVRI 2026 Dublin - register now!
Be part of our 20th anniversary celebrations in Dublin! Registration for PVRI 2026 is open — secure your place at this landmark Congress today.
Already registered? Don’t forget to book your accommodation early to guarantee the best rates near the venue.
Our PVRI Digital Webinar Series alternates between 'Cutting Edge Innovation in Clinical & Experimental PH' and 'Living Legends in PH: History & Personal Perspectives' sessions. Don't miss out!
This November, we’re coming together as one global team to shine a light on PH research and innovation during PH Awareness month through our new fundraising challenge: Breath Beyond Borders. PVRI friends across the world are taking on a personal challenge that pushes their limits. Find out how you can get involved.
Join us 28 January – 1 February as we celebrate 20 years of progress and innovation in PH. This year’s programme highlights advances in PAH, CTEPH, and PH in lung disease, with sessions on emerging therapies, precision medicine, and future directions.
Part of the Latin America Task Force new webinar series, this session aims to evaluate PH and differential diagnosis, and the differences in phenotype presentations in Latin America and USA / Europe.
PAH is classically described as a disease in young adults, with no comorbidities. However, recent registries showed the epidemiology has changed to older patients with comorbidities (obesity, diabetes, hypertension, and coronary heart disease). In contrast, in Latin America, registries have shown that PAH patients are younger and have fewer comorbidities, which raises the question of whether Latin American patients present with a different phenotype.
In the late 1940s, the US Air Force recorded an unacceptable number of crashes and emergency landings, prompting a formal enquiry. It was resolved that neither the engine nor the pilot was at fault. Attention turned instead to the design of the cockpit, which was based on the ‘average’ airman from 1926.
Pulmonary Hypertension (PH) is a critical disease characterized by increased pulmonary arterial pressure and the development of vascular resistance, which can lead to fatal outcomes if left untreated. Cardiovascular and Respiratory Nurses (CRNs) play a significant role in the management of PH; however, there is a lack of sufficient studies examining their role competence.
Using lung immunohistochemistry and stereology, platelets were found to accumulate and co-localize with leukocytes, particularly monocytes, within the mural and adventitial space of remodeled vessels of patients with pulmonary arterial hypertension.
Our Pulmonary Hypertension Global Patient Survey (PHGPS), the largest survey to date to explore the perspectives of patients with PH at a global scale, has released initial findings from its adult cohort of 3,329 patients living with PH.
We’re excited to announce the relaunch of the PVRI Digital Webinar Series, beginning September 2025. This free monthly series, open to all, brings together the global PH community for keynote presentations, rich discussion, and the opportunity to learn cutting-edge new research.
This PH Awareness Month, we’re inviting you to join the global PVRI community for our very first Breath Beyond Borders challenge. Throughout November, PVRI members and friends around the world will be taking on personal challenges — walking, running, cycling, speed skating, or even playing the piano — to shine a light on PH research and innovation, and raise funds for PVRI along the way.
We’re thrilled to announce a new chapter in the leadership of PVRI’s Innovative Drug Discovery Initiative (IDDI). We warmly welcome industry reps, Gil Golden (UTC) and Sidra Hoffman (Gossamer Bio), to the IDDI Leadership Team. They’ll be joining Sandeep Sahay and Luke Howard, who remain on as IDDI Leaders.
